Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01080664 · ClinicalTrials.gov registry record · Phase 1
A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies
A Phase 1 study, sponsored by EMD Serono.
- Terminated
- Registry status
- Phase 1
- Development phase
- 124
- Enrollment target
NCT01080664 is a Phase 1 study that was terminated before completion, run by EMD Serono. The registered enrollment target is 124 participants.
The verdict
NCT01080664, a Phase 1 study, was terminated before completion, sponsored by EMD Serono.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 124 participants
- Enrollment target
Study Summary
EMD Serono decided to terminate enrollment based on a review of the available clinical data and low probability of completing the trial based on the observed recruitment rate. Subjects already enrolled in the study continued participation in the study, consistent with the protocol, to study completion.
Interventions
- DRUG AS703569
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2006-12 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01080664
The ClinicalTrials.gov registry entry for NCT01080664 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AS703569 is the first listed.
NCT01080664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01080664 about?
NCT01080664 is a clinical study titled "A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies". EMD Serono decided to terminate enrollment based on a review of the available clinical data and low probability of completing the trial based on the observed recruitment rate. Subjects already enrolled in the study continued participation in the study, consistent with the protocol, to study completi...
What is the current status of trial NCT01080664?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 124 participants. The study started on 2006-12. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01080664?
The interventions under investigation include: AS703569 (DRUG).
Who is sponsoring clinical trial NCT01080664?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.